Abstract
Background: Fever and inflammation are a hallmark of clinical Plasmodium falciparum (Pf) malaria induced by circulating asexual parasites. Although clinical manifestations of inflammation are associated with parasite density, this relationship is influenced by a complex network of immune-modulating factors of both human and parasite origin. Methods: In the Controlled Human Malaria infection (CHMI) model, we compared clinical inflammation in healthy malaria-naïve volunteers infected by either Pf-infected mosquito bites (MB, n=12) or intravenous administration of Pf-infected red blood cells (BS, n=12). Findings: All volunteers developed patent parasitaemia, but both the incidence and duration of severe adverse events were significantly higher after MB infection. Similarly, clinical laboratory markers of inflammation were significantly increased in the MB-group, as well as serum pro-inflammatory cytokine concentrations including IFN-γ, IL-6, MCP1 and IL-8. Parasite load, as reflected by maximum parasite density and area under the curve, was similar, but median duration of parasitaemia until treatment was longer in the BS-group compared to the MB-group (8 days [range 8 – 8 days] versus 5·5 days [range 3·5 – 12·5 days]). The in vitro response of subsets of peripheral blood mononuclear cells showed attenuated Pf-specific IFNγ production by γδ T-cells in the BS-arm. Interpretation: In conclusion, irrespective the parasite load, Pf-infections by MB induce stronger signs and symptoms of inflammation compared to CHMI by BS infection. The pathophysiological basis remains speculative but may relate to induced immune tolerance. Funding: The trial was supported by PATH's Malaria Vaccine Initiative; the current analyses were supported by the AMMODO Science Award 2019 (TB).
| Original language | English |
|---|---|
| Article number | 103919 |
| Journal | EBioMedicine |
| Volume | 77 |
| DOIs | |
| Publication status | Published - Mar 2022 |
Bibliographical note
Funding Information:RS received consulting fees from Biomedical Primate Research Centre, Rijswijk, The Netherlands and has stocks in TropIQ Health Sciences, TropIQ, the Netherlands. MA was supported by PATH's Malaria Vaccine Initiative. ZY was supported by the AMMODO science award 2019 awarded to TB. All other authors: No reported conflicts.
Funding Information:
The original trial was supported by PATH's Malaria Vaccine Initiative; the current analyses and ZY were supported by the AMMODO science award 2019 awarded to TB. The authors thank all staff from the Radboudumc Technology Center Clinical Studies, Daphne Smit and Annemieke Jansens for project guidance during the trial. We thank Kjerstin Lanke, Karina Teelen, Youri van Waardenburg and Rianne Stoter for performing qPCRs and PBMC isolations, Geert-Jan van Gemert, Marga van de Vegte-Bolmer, Wouter Graumans, Roel Heutink, Rianne Stoter, Laura Pelser, Jolanda Klaassen, Astrid Pouwelsen, and Jacqueline Kuhnen for the mosquito infection and dissection work, Foekje Stelma, Cindy Handgraaf and all thick smear microscopists for reading many smears. We thank James McCarthy for providing the P. falciparum?infected human erythrocytes. Finally, the authors thank all volunteers who participated in the study. The clinical trial protocol is available at ClinicalTrials.gov and as supplementary material, identifier NCT03454048. All underlying data will be accessible from the date this work is published on Dryad https://datadryad.org/stash/share/epMQtmqTzeXfKSDoY_7tMWTqLESQV4ftxrGjz8G55M4.
Publisher Copyright:
© 2022 The Authors
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of '"Controlled human malaria infections by mosquito bites induce more severe clinical symptoms than asexual blood-stage challenge infections"'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver